Categories

News

AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
2026-09-01
An estimated 69,000 Americans acquired hepatitis C in 2023, roughly double the mid-2010s rate, even though the disease has been curable with an eight- to 12-week course of oral antivirals for more than a decade. AbbVie’s MAVYRET became the first of those antivirals cleared for acute infection in June 2025, with a 96% cure rate in trial. In the EU, the drug, billed as MAVIRET, won extended approval to treat acute hepatitis C virus infections in June 2026.
UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies
2026-08-31
Since both Novartis’ and Bristol Myers Squibb’s assets were developed using rapid manufacturing platforms, analysts from William Blair suggested, "that rapid manufacturing could be driving increased cell expansion and the reported toxicities." (iStock / Getty Images Plus)
As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%
2026-08-28
2022 was a big year for layoffs in biopharma. So were the next three. Novartis, for instance, outlined plans to cut up to 8,000 jobs in 2022, after pharmaceutical industry job cuts jumped 280% in 2021.
Exercise-Boosting Molecule May Help Improve Muscle Health in Type 2 Diabetes
2026-08-21
Led by the University of Leeds, this international study identifies L-BAIBA, an exercise-induced metabolite, as a key regulator of skeletal muscle adaptation. L-BAIBA boosts muscle strength and endurance, protects against type 2 diabetes-related muscle damage, and holds therapeutic potential for sarcopenia, cancer cachexia and heart failure. Published in Nature Communications, the work reveals how exercise signals reshape muscle metabolism and function.
lab on a chip Human Multi-Organ Chip Offers New Insight Into Cancer Metastasis
2026-08-21
Researchers developed a human multi‑organ chip featuring engineered bone and lung tissues connected by vascular flow to recapitulate organ‑specific breast cancer metastasis. Published in Science Translational Medicine, this patient‑compatible model reproduces cancer cell extravasation, organ colonization and pre‑metastatic niche formation. It enables mechanistic study of metastatic progression and supports discovery of anti‑metastasis therapeutic targets, complementing traditional animal preclin
Scientists Analyze 267 Receptors That Control Protein Fate in Rare Diseases
2026-08-21
Scientists at Warsaw’s IIMCB have generated the‑first systematic catalog covering 267 cullin‑RING ligase substrate receptors, with 93 receptors associated with genetic diseases. Published in Trends in Cell Biology, the review explores how genetic variants in these receptors drive disease phenotypes, especially neurodevelopmental and neuromuscular symptoms, offering a reference resource for rare‑disease variant interpretation and targeted protein‑degradation therapeutic research.
The 50 best-funded biotech companies of 2026
2026-08-14
This ranking tracks 50 private biotechs that announced or disclosed financing between January 1 and August 12, 2026, based on cumulative equity raised. Isomorphic Labs, despite raising $2.7 billion, is excluded due to Alphabet's majority control, leaving Rakuten Medical at the top with over $809 million. Earendil Labs ($787M) and NewLimit ($760M) round out the top three, focusing on AI-driven biologics and longevity medicine, respectively.
In Vitro Diagnostic Industry in China - Urine
2026-08-03
This overview examines China’s urinalysis market landscape, major players including URIT, DIRUI and AVE, and the latest technological innovations. It covers urine dry chemistry analyzers, urine formed element analyzers powered by AI image recognition, and emerging one-stop multi-dimensional workflows integrating urine-specific protein testing. It also highlights URIT’s UC‑1800 automatic urine analyzer and future trends of urinary proteomics, metabolomics and genomics testing.
Go to page
CONTACT US
Name *
Email *
Message *
Verification code *
Click to verify